Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1
Research output: Contribution to journal › Journal article › peer-review
Documents
- Fulltext
Accepted author manuscript, 15.2 MB, PDF document
Human leukocyte antigen (HLA)-independent, T cell–mediated targeting of cancer cells would allow immune destruction of malignancies in all individuals. Here, we use genome-wide CRISPR–Cas9 screening to establish that a T cell receptor (TCR) recognized and killed most human cancer types via the monomorphic MHC class I-related protein, MR1, while remaining inert to noncancerous cells. Unlike mucosal-associated invariant T cells, recognition of target cells by the TCR was independent of bacterial loading. Furthermore, concentration-dependent addition of vitamin B-related metabolite ligands of MR1 reduced TCR recognition of cancer cells, suggesting that recognition occurred via sensing of the cancer metabolome. An MR1-restricted T cell clone mediated in vivo regression of leukemia and conferred enhanced survival of NSG mice. TCR transfer to T cells of patients enabled killing of autologous and nonautologous melanoma. These findings offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies.
Original language | English |
---|---|
Journal | Nature Immunology |
Volume | 21 |
Issue number | 2 |
Pages (from-to) | 178-185 |
Number of pages | 8 |
ISSN | 1529-2908 |
DOIs | |
Publication status | Published - 2020 |
Bibliographical note
Author Correction: https://doi.org/10.1038/s41590-020-0640-6
Links
- http://europepmc.org/articles/pmc6983325?pdf=render
Accepted author manuscript
ID: 235774868